Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
=============================================================================================================================================

* Sophia Frentzas
* Anna Rachelle Austria Mislang
* Charlotte Lemech
* Adnan Nagrial
* Craig Underhill
* Wenjing Wang
* Zhongmin Maxwell Wang
* Baiyong Li
* Yu Xia
* Jermaine I G Coward